齐拉西酮与奥氮平对首发精神分裂症患者糖脂代谢的影响

Effects of ziprasidone and olanzapine on glucolipid metabolism of first-episode schizophrenia patients

目的探讨齐拉西酮与奥氮平对首发精神分裂症患者糖脂代谢的影响。方法将54例首发精神分裂症患者采用随机数字表法分为两组，每组27例，齐拉西酮组采用齐拉西酮治疗，奥氮平组采用奥氮平治疗，比较两组的临床疗效和糖脂代谢指标。结果齐拉西酮组总有效率为81．5％，奥氮平组为88．9％，两组比较差异无显著性（P〉0．05）。治疗后齐拉西酮组糖脂代谢各项指标检查结果与治疗前比较差异均无显著性（P〉0．05），奥氮平组除高密度脂蛋白，其余指标均较治疗前显著升高（P〈0．05或0．01），且显著高于齐拉西酮组（P〈0．05）。结论齐拉西酮与奥氮平治疗首发精神分裂症患者疗效相当，但齐拉西酮对患者的糖脂代谢影响较小。

Objective To explore the effects of ziprasidone and olanzapine on glucolipid metabolism of first-episode schizophrenia patients. Methods According to random number table fifty-four first-episode schizophrenia patients were assigned to two groups of 27 ones each treated with ziprasidone and olanzapine respectively and efficacy and glueolipid metabolism indexes compared between 2 groups. Results The total effective rate was respectively 81.5% in ziprasidone and 88.9% in olanzapine group and group difference wasn＇t significant （P〉0.05）. After treatment the examination results of all indexes had no signifi- cant differences from those before treatment in ziprasidone group （P〉0.05）, all indexes heightened more significantly in olanzapine （P〈0.05 or 0.01） and than in ziprasidone group （P〈0.05） except high density lipoprotein. Conclusion Ziprasidone has equivalent efficacy to olanzapine in first-episode schizophrenia patients, but the former has less influence on glucolipid metabolism.